About Epygenix
Epygenix is a Healthcare company based in Paramus (United States) founded in 2016. It develops drugs for rare neurological disorders including sleep, neurobehavioral, and epilepsy conditions. It operates on a B2B model. Epygenix offers products and services including Pitolisant, ZYN002, EPX-100, and BP1.15205. Its focus areas include Biotechnology, Neurobehavioral, Rare Diseases and Neurology. Its legal entity is Harmony Biosciences Management, Inc. Similar companies include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed similar companies have raised funding.
Company details
Harmony Biosciences is a biotechnology company that focuses on creating innovative treatments for rare neurological diseases via a patient-centered drug development model. They maintain a pipeline of compounds targeting sleepwake disorders, neurobehavioral issues, and rare epilepsy through clinical trials and licensing partnerships. Headquartered in Plymouth Meeting, Pennsylvania, they address unmet medical needs for patients with conditions like narcolepsy and Fragile X syndrome.
- Headquarters Paramus, United States
- SectorsHealthcare
- Email••••••••
- Website epygenix.com
- Social LinkedIn X Instagram
- Legal Name Harmony Biosciences Management, Inc.
Products & Services of Epygenix
Epygenix offers a comprehensive portfolio of products and services, including Pitolisant, ZYN002, EPX-100, and BP1.15205.
Drug for excessive daytime sleepiness in narcolepsy patients.
Gel for behavioral symptoms in Fragile X syndrome.
Modulates serotonin for Dravet and Lennox-Gastaut syndromes.
Orexin-2 receptor agonist for narcolepsy symptoms.
Similar companies to Epygenix
Epygenix has 3 listed similar companies in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed similar companies of Epygenix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Epygenix (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epygenix
Complete news archive for Epygenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epygenix
Epygenix was founded in 2016.
Epygenix is headquartered in Paramus, United States. It is registered at Paramus, New Jersey, United States.
Harmony Biosciences is a biotechnology company that focuses on creating innovative treatments for rare neurological diseases via a patient-centered drug development model. They maintain a pipeline of compounds targeting sleepwake disorders, neurobehavioral issues, and rare epilepsy through clinical trials and licensing partnerships. Headquartered in Plymouth Meeting, Pennsylvania, they address unmet medical needs for patients with conditions like narcolepsy and Fragile X syndrome.
Epygenix's top competitors include BridgeBio, Forge Biologics and Insitro.
Epygenix offers Pitolisant, ZYN002, EPX-100, and BP1.15205.
Epygenix operates through Harmony Biosciences Management, Inc..